Corcept Therapeutics

Corcept Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing drugs that modulate cortisol activity. Founded in 1998 by psychiatrists Joseph K. Belanoff and Alan Schatzberg, the company focuses on addressing severe metabolic, psychiatric, oncologic, and endocrine disorders linked to excess cortisol. The flagship product, Korlym® (mifepristone), received FDA approval in 2012 as the first treatment for hypercortisolism associated with Cushing’s syndrome. Korlym blocks cortisol receptors to mitigate the harmful effects of excess cortisol. Corcept has a robust pipeline of over 1,000 selective cortisol modulators and is conducting more than 30 clinical studies across various disease areas, including endocrinology, oncology, metabolism, and neurology. Corcept Therapeutics aims to improve patients' lives by addressing significant unmet medical needs through innovative therapies. The company collaborates with a global network of scientists and clinicians and employs over 400 professionals to advance its mission in cortisol modulation.